Swedish Orphan Biovitrum AB (publ)
Stockholm Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Swedish Orphan Biovitrum AB (publ) (Sobi) is a Sweden-based biopharmaceutical company headquartered in Stockholm and founded in 2001 that specializes in developing, manufacturing and commercializing innovative therapies for rare diseases, with a primary focus on haematology, immunology and specialty care; its core products and services include Elocta and Alprolix for haemophilia A and B treatment, Doptelet (avatrombopag) for immune thrombocytopenia and chemotherapy-induced thrombocytopenia, Kineret (anakinra) for rare inflammatory disorders including systemic juvenile idiopathic arthritis and recurrent pericarditis, Gamifant (emapalumab) for primary haemophagocytic lymphohistiocytosis, Synagis (palivizumab) for respiratory syncytial virus prevention in high-risk infants, Orfadin, Ammonaps and Ammonul for genetic and metabolic disorders, as well as partner products encompassing around 40 specialty pharmaceuticals in haematology, oncology and emergency care, and manufacturing services for recombinant proteins such as ReFacto/Xyntha under agreement with Pfizer. Sobi operates across Europe, North America and other international markets through subsidiaries in countries including Sweden, Denmark, Finland, Norway, the United Kingdom, France and the United States, targeting patients with orphan and niche conditions in inflammation, genetics, metabolism and supportive care segments. Recent developments include a revised 2025 full-year outlook announced in October 2025 projecting low double-digit revenue growth at constant exchange rates and mid-to-high 30s adjusted EBITA margin, driven by strong year-to-date performance from Doptelet and Gamifant alongside cost efficiencies from organizational realignments; regulatory filings for label expansions such as Gamifant in secondary haemophagocytic lymphohistiocytosis and secondary HLH, Aspaveli (pegcetacoplan) in nephrology, NASP for acute graft-versus-host disease with mid-2026 FDA review, and CEL212; progression of phase 2/3 trials for Bonviva (vorasidenib) in VEXUS syndrome following FDA IND clearance; and the 2023 acquisition of CTI BioPharma to bolster its haematology portfolio.
Sobi to present new data on pegcetacoplan at ERA 2026
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM
Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030
Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030
Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress
Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress
Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026
Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook
Invitation: Sobi's Q4 and FY 2025 report
Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data
Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data
Save the Date: Sobi to host a Capital Markets Day on 18 February 2026
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN